Baird lowered the firm’s price target on Ultragenyx (RARE) to $40 from $47 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Launches Restructuring Plan to Cut Costs
- Ultragenyx reports Q4 EPS ($1.29), consensus ($1.17)
- Ultragenyx sees FY26 revenue $730M-$760M, consensus $790.67M
- RARE Upcoming Earnings Report: What to Expect?
- Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating